Poster: ABCL-334 Long-Term Survival Projections of Loncastuximab Tesirine-Treated Patients in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Mehdi Hamadani(Medical College of Wisconsin), Carmelo Carlo‐Stella(Humanitas University), Christopher N. Graham, Weiyun Z. Ai(City College of San Francisco), Kate Zhang, Lei Chen(Astrophysique Relativiste, Théories, Expériences, Métrologie, Instrumentation, Signaux), David Ungar, Laura Liao(Providence College), Hannah Strat
Clinical Lymphoma Myeloma & Leukemia
September 20, 2022
10.1016/s2152-2650(22)01003-5
Cited by 0

Related Papers

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487